Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) is a clinical-stage biopharmaceutical company developing targeted protein degradation medicines in oncology, autoimmune disease and inflammatory conditions. The NRIX news feed on Stock Titan aggregates company announcements, clinical updates and regulatory disclosures so readers can follow how its pipeline and collaborations evolve over time.
News about Nurix frequently centers on clinical trial results and milestones for its lead programs. Recent releases describe new and updated data from Phase 1a/1b studies of the BTK degrader bexobrutideg (NX-5948) in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and Waldenström macroglobulinemia, including objective response rates, durability of responses and safety findings. Additional updates cover translational and clinical data for NX-1607, an oral CBL-B inhibitor for solid tumors, highlighting immune activation, tumor microenvironment remodeling and disease control in heavily pretreated patients.
Investors and clinicians can also use the NRIX news page to track corporate and regulatory events such as the initiation of the pivotal DAYBreak CLL-201 Phase 2 study, plans for a confirmatory Phase 3 trial, expansion of bexobrutideg into autoimmune and inflammatory indications, and participation in major medical and investor conferences including the American Society of Hematology (ASH), the Society for Immunotherapy of Cancer (SITC) and the J.P. Morgan Healthcare Conference.
Nurix’s news flow further includes announcements on strategic collaborations and governance, such as progress in partnered STAT6 and IRAK4 degrader programs with Sanofi and Gilead, and board appointments that add drug development and commercialization experience. Bookmark this page to access a consolidated view of NRIX press releases and related coverage as the company advances its targeted protein degradation pipeline.
Nurix Therapeutics (Nasdaq: NRIX) announced promising initial results from the NX-2127 clinical trial for patients with diffuse large B cell lymphoma (DLBCL). A patient achieved a complete response at 8 weeks, confirmed at 16 weeks, after receiving 300 mg of NX-2127 daily. This dual-action drug targets Bruton’s tyrosine kinase (BTK) and aids in degrading key proteins linked to tumor proliferation. The NX-2127 trial shows potential for addressing unmet medical needs in aggressive lymphomas, with further updates expected at the upcoming American Society of Hematology meeting in December.
Nurix Therapeutics (Nasdaq: NRIX) announced plans to present at the 5th Annual TPD Summit from October 25-28, 2022, in Boston, MA. A Keynote Plenary will be delivered by Arthur T. Sands, M.D., Ph.D., the CEO, discussing advancements in BTK degraders for hematologic malignancies. Other presentations include topics on targeted protein degradation and orally active, brain-penetrant degraders. Nurix focuses on developing therapies that modulate cellular protein levels, utilizing their DELigase discovery platform.
Nurix Therapeutics reported Q3 2022 results, highlighting a gross revenue of $10.8 million, up from $10.3 million in Q3 2021. The company raised $95 million from two registered direct offerings in July, bolstering its cash position to $413.6 million as of August 31, 2022. R&D expenses rose to $47.8 million, reflecting increased clinical activities, while net loss was $45.7 million or $0.90 per share. Nurix expanded its leadership team and announced six presentations at the SITC 2022 annual meeting, including initial data for its NX-1607 program.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced six poster presentations for the Society for Immunotherapy of Cancer’s 37th Annual Meeting from November 8-12, 2022, in Boston. The presentations highlight the company’s targeted protein modulation platform and CBL-B inhibitors, including NX-1607 and DeTIL-0255. Key data to be presented includes initial biomarker data from a Phase 1 trial of NX-1607 in patients with advanced malignancies. These advancements could enhance anti-tumor immunity and broaden treatment options for various cancer types.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) has appointed Edward C. Saltzman to its board of directors, enhancing its strategic capabilities in drug development. With over 30 years of experience in the biopharmaceutical sector, Saltzman currently leads Biotech Strategy at Lumanity Inc. His expertise is expected to significantly contribute as Nurix advances its drug pipeline targeting cancer treatments. CEO Arthur T. Sands expressed optimism about Saltzman's role in the company's growth, specifically highlighting Nurix’s DELigase platform designed to modulate protein levels for innovative cancer therapies.
Nurix Therapeutics (Nasdaq: NRIX) announced that Arthur T. Sands, M.D., Ph.D., will participate in two significant conferences in September 2022. The presentations include a Fireside chat at the Wells Fargo Healthcare Conference on September 7 from 3:45 to 4:15 p.m. ET, and another at the Baird 2022 Global Healthcare Conference on September 13 from 10:50 to 11:20 a.m. ET. These events will be webcast live, with recordings available for approximately 30 days. Nurix specializes in targeted protein modulation for treating cancer.
Nurix Therapeutics (Nasdaq: NRIX) announced the appointment of Eric Schlezinger as Chief People Officer. With extensive experience in biopharma HR, Schlezinger aims to enhance leadership and talent acquisition as Nurix expands its oncology pipeline. CEO Arthur Sands highlighted Schlezinger's strengths in building company culture and recruiting top talent. Previously, Schlezinger led HR at Adamas Pharmaceuticals and Vir Biotechnology, contributing to their growth and transitions to public companies. Nurix focuses on targeted protein modulation for cancer treatment, utilizing E3 ligases in their drug discovery.
Nurix Therapeutics (Nasdaq: NRIX) announced a registered direct offering of pre-funded warrants to purchase 2,869,440 shares of common stock at a price of $13.939 per warrant, raising approximately $40 million. The transaction with two healthcare-focused investment funds is expected to close on July 11, 2022. Proceeds will support clinical trials, manufacturing, and research, allowing Nurix to fund operations into the second half of 2024. The offering is conducted under an effective shelf registration statement and will not constitute an offer to sell securities in any unlawful jurisdiction.
Nurix Therapeutics (Nasdaq: NRIX) announced a registered direct offering of pre-funded warrants to purchase 3,945,480 shares of common stock at $13.939 per warrant, totaling approximately $55 million in gross proceeds. The offering is expected to close on July 11, 2022. Proceeds will support clinical trials, manufacturing, research, and other corporate purposes, aiming to fund operations into the second half of 2024. The financing includes participation from Redmile Group. The pre-funded warrants were offered under a previously filed shelf registration statement with the SEC.
Nurix Therapeutics, Inc. (NRIX) announced advancements in its clinical programs, including the initiation of Phase 1b for NX-2127 in chronic lymphocytic leukemia (CLL) due to promising Phase 1a results. The first patient was dosed in the Phase 1a trial for NX-5948 targeting B-cell malignancies. Financially, collaboration revenue rose to $11.4 million, driven by partnerships with Gilead and Sanofi. However, the net loss increased to $45.4 million for Q2 2022. As of May 31, 2022, cash and investments stood at $348.8 million.